您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Deflazacort(MDL 458)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Deflazacort(MDL 458)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Deflazacort(MDL 458)图片
CAS NO:14484-47-0
规格:≥98%
包装与价格:
包装价格(元)
50mg电议
100mg电议
250mg电议
500mg电议
1g电议
5g电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)441.52
FormulaC25H31NO6
CAS No.14484-47-0
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 88 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: 12 mg/mL (27.1 mM)
SMILESCC(OCC(C12N=C(C)OC1CC3C(CCC4=CC(C=C[C@@]45C)=O)C5[C@@H](O)C[C@@]32C)=O)=O
SynonymsMDL 458; Cortax; Decortil; Deflanil; Flezacor; ML-458; ML458; DL-458-IT, L-5458; trade name: Emflaza
实验参考方法
In Vitro

In vitro activity: Deflazacort (also known as MDL 458; trade name: Emflaza) is a glucocorticoid used as an anti-inflammatory and immunosuppressant. It was approved by FDA in 2017 to treat patients age 5 years and older with Duchenne muscular dystrophy (DMD). Deflazacort is an inactive prodrug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.

In VivoDeflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats. Deflazacort reduces thymus weight and Daily weight gain in rats. Deflazacort lowers liver IFG-I and GHR mRNA in rats. Deflazacort (DFC) is a heterocyclic glucocorticoid with anti-inflammatory activity but with decreased side effects. Deflazacort and [3H]dexamethasone (DEX) similarly induce in vivo ornithine decarboxylase activity in hippocampus and liver, although body weight loss after chronic treatment is significantly less for DFC. Deflazacort induces dose-dependent decreases in osteocalcin (OC) plasma production rate (PPR). Deflazacort and prednisolone increase both postabsorptive plasma glucose and plasma calcium levels in sheep, but there are no significant differences between their effects. Deflazacort, especially combined with L-arginine, spares quadriceps muscle from injury-induced regeneration (myf5 expression) compared with placebo treatment, despite an increase in membrane permeability immediately after exercise. Deflazacort alone prevents the typical progressive loss of function (measured as voluntary distance run over 24 hours) that is observed 3 months later in placebo-treated mice. Deflazacort causes a less significant alteration in the pattern of GH secretion and does not negatively affect the overall amount of GH secreted.
Animal modelDeflazacort results in a significant and equal decrease of thymus weight, indicating a marked reduction in total immunogenic tissue in rats. Deflazacort reduces thymus weight and Daily weight gain in rats. Deflazacort lowers liver IFG-I and GHR mRNA in rats.
Formulation & DosageN/A
ReferencesNeuropharmacology. 2012 Jun;62(7):2261-6; Eur J Endocrinol. 1994 Dec;131(6):652-7.